Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 4/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
| ▸ | CYP17A1 | P05093 | 10/20 | 0.66 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GUSB | P08236 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333841 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL1418667 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL29934843 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL10301223 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL3363388 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL1419890 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL29934586 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| SCHEMBL29934837 | 1.00 | SHBG (0.70) | SHBGSERPINA6ESR1ARESR2 | |
| Sulfuric Acid SCHEMBL22717101 | 0.94 | SHBG (0.63) | SHBGSERPINA6ESR1ARESR2 | |
| Sulfuric Acid SCHEMBL22717128 | 0.94 | SHBG (0.63) | SHBGSERPINA6ESR1ARESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | claimed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | claimed |
| EP-2486924-B1 | Drugs and uses | NEURMEDIX INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070265236-A1 | Asthma Treatment Methods | BIOVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070213309-A1 | Sepsis Treatment Methods | BIOVIE INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070203107-A1 | Pharmaceutical compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20050195943-A1 | Method of forming subtraction images | FUJI PHOTO FILM CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | SHBG 92/4885SERPINA6 208/4885ESR1 220/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | SHBG 92/4885SERPINA6 208/4885ESR1 220/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | SHBG 55/4885SERPINA6 194/4885ESR1 154/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | SHBG 104/4885SERPINA6 432/4885ESR1 200/4885 |
| US-20050075321-A1 | Neurological disorder treatment methods | HSD17B1, HSD17B3, HSD3B1 | SHBG 157/4885SERPINA6 78/4885ESR1 1820/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | SHBG 102/4885SERPINA6 421/4885ESR1 192/4885 |
| US-20070265236-A1 | Asthma Treatment Methods | HSD3B1, HSD3B2, HSD17B13 | SHBG 178/4885SERPINA6 228/4885ESR1 216/4885 |
| US-20050101581-A1 | Therapeutic treatment methods 2 | HSD3B2, HSD3B1, HSD17B2 | SHBG 100/4885SERPINA6 176/4885ESR1 259/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | SHBG 93/4885SERPINA6 119/4885ESR1 354/4885 |
| US-20070213309-A1 | Sepsis Treatment Methods | HSD3B1, ELANE, HSD3B2 | SHBG 119/4885SERPINA6 257/4885ESR1 114/4885 |
| US-20070203107-A1 | Pharmaceutical compositions | HSD3B1, HSD3B2, HSD17B13 | SHBG 107/4885SERPINA6 288/4885ESR1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.